以结构为导向的胆酸衍生物的发现,用于治疗肝脏疾病而不会引起
Jun Yang1, Tianjun Zhao2, Junping Fan3
1Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
Cell
|October 30, 2024
概括
研究人员发现胆汁酸激活一种受体 (MRGPRX4), 通过阻断这种激活,
科学领域:
- 生物化学
- 药理学
- 肝病学
背景情况:
- 慢性是肝脏疾病的严重症状,
- 激活MRGPRX4受体 (hX4) 的胆汁酸与胆汁有关,但机制尚不清楚.
研究的目的:
- 通过MRGPRX4激活来阐明胆酸诱导的的机制.
- 开发一种治疗肝病相关的和肝损伤的药物.
主要方法:
- 已确定与相关的3硫酸胆汁酸 (BAs).
- 确定了hX4受体的冷EM结构与胆汁酸模仿.
- 设计和合成了一种新的胆酸衍生物 (化合物7).
主要成果:
- 冷-EM结构显示了hX4中独特的联结口袋,强调了BA上3基对受体激活的重要性.
- 化合物7缺乏3基,有效抑制了hX4的激活.
- 在临床前肝病模型中,化合物7在减轻肝损伤和纤维化方面表现出有效性.
结论:
- 胆汁酸的3基对激活MRGPRX4受体至关重要,这是胆汁的关键驱动因素.
- 一种新的胆汁酸衍生物,化合物7显示治疗肝脏疾病并发症的潜力,包括和器官损伤.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
Hepatic Drug Excretion: Enterohepatic Cycling
1.1K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.1K
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
Hepatic Drug Excretion: Influencing Factors
94
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
94
Drugs for Treatment of Constipation-Predominant IBS
139
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
139


